Which has the lower trailing P/E, ASND or EHC?

ASND has the lower trailing P/E: ASND trades at 17.33 and EHC at 19.70. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ASND or EHC?

Over the past five years, ASND grew revenue faster — ASND at a 189.92% CAGR versus EHC at 4.81%.

Does ASND or EHC pay a bigger dividend?

EHC pays a dividend (0.63% yield), while ASND has no payments in the available dividend history.

Is ASND or EHC more profitable?

ASND runs the higher net margin — ASND at 71.08% versus EHC at 10.01%.

How have ASND and EHC total returns compared?

Over the past 10 years, ASND delivered 27.41% and EHC delivered 15.79% annualized total return. Past performance doesn't predict future results.

Ascendis Pharma A/S (ASND) vs Encompass Health Corporation (EHC)

A side-by-side comparison of Ascendis Pharma A/S and Encompass Health Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ASND

Ascendis Pharma A/S

$14.16B

$228.03HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

EHC

Encompass Health Corporation

$12.00B

$120.97HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ASND vs EHC

growth of $100 · dividends reinvested · last 10y

ASND +1027.2% (+27.4%/yr)EHC +326.5% (+15.6%/yr)ASND compounded faster over this window

ASND EHC

ASND vs EHC: by the numbers

•ASND is the larger company ($14.16B vs $12.00B market cap).
•ASND trades at the lower trailing earnings multiple (17.33 vs 19.70 P/E), one valuation lens rather than an overall verdict.
•ASND converts more revenue to profit (71.08% vs 10.01% net margin).
•ASND grew revenue faster over the past five years (189.92% vs 4.81% CAGR).
•EHC pays a dividend (0.63% yield), while ASND has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	ASND	EHC
P/E ratio	17.33	19.70
Forward P/E	N/A	19.79
PEG ratio	N/A	1.39
P/S ratio	11.59	1.93
P/B ratio	8.64	4.62
EV / EBITDA	93.79	10.07
FCF yield	2.73%	3.44%

Profitability

Metric	ASND	EHC
Gross margin	90.18%	95.71%
Operating margin	-18.92%	18.00%
Net margin	71.08%	10.01%
ROE	52.97%	23.91%
ROIC	5.85%	13.42%

Dividends

Metric	ASND	EHC
Dividend yield	N/A	0.63%
Payout ratio	N/A	12.38%

Growth (annualized)

Metric	ASND	EHC
Revenue CAGR (5Y)	189.92%	4.81%
EPS CAGR (5Y)	N/A	14.39%
FCF CAGR (5Y)	N/A	0.28%
Total return CAGR (5Y)	7.40%	17.12%

Frequently asked

Which has the lower trailing P/E, ASND or EHC?: ASND has the lower trailing P/E: ASND trades at 17.33 and EHC at 19.70. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ASND or EHC?: Over the past five years, ASND grew revenue faster — ASND at a 189.92% CAGR versus EHC at 4.81%.
Does ASND or EHC pay a bigger dividend?: EHC pays a dividend (0.63% yield), while ASND has no payments in the available dividend history.
Is ASND or EHC more profitable?: ASND runs the higher net margin — ASND at 71.08% versus EHC at 10.01%.
How have ASND and EHC total returns compared?: Over the past 10 years, ASND delivered 27.41% and EHC delivered 15.79% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ASND analysis Full EHC analysis Interactive comparison tool

Dig into the metrics

Ascendis Pharma A/S P/E ratio Encompass Health P/E ratio Encompass Health dividend yield Ascendis Pharma A/S ROE Encompass Health ROE Ascendis Pharma A/S operating margin Encompass Health operating margin Ascendis Pharma A/S revenue growth Encompass Health revenue growth Ascendis Pharma A/S free cash flow Encompass Health free cash flow

Ascendis Pharma A/S & Encompass Health appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.